At the Peripheral Nerve Society congress (8-12 July 2017, Sitges, Spain), Professor Satoshi Kuwabara from the Department of Neurology at Chiba University, Japan, announced the results of a randomized placebo-controlled phase 2 trial with eculizumab in patients with Guillain-Barré syndrome. Eculizumab is a monoclonal antibody that by binding to C5 inhibits complement activation. At 24 weeks, marked improvement in motor function was observed in patients treated with eculizumab (Alexion Pharmaceuticals Inc).
The abstract can be found here on page 206 http://www.theoffice.it/wp-content/uploads/2017/06/2017PNS_Final_Programme_WEB.pdf
by Peter Van den Bergh, Co-Chair of the Scientific Panel ‘Neuropathies’
